Emmaus Life Sciences Reports 38% Decline in Net Revenues for Q3 2025

Reuters

Nov 15, 2025

<a href="https://laohu8.com/S/EMMA">Emmaus Life</a> Sciences Reports 38% Decline in Net Revenues for Q3 2025

Emmaus Life Sciences Inc. reported net revenues of $3.4 million for the three months ended September 30, 2025, a 38% decrease compared to $5.5 million in the same period in 2024. The decline was attributed to competition from generic L-Glutamine in the U.S. and lower sales in the Middle East North Africa region. Operating expenses were reduced to $2.4 million from $4.3 million, reflecting cost-cutting measures implemented in the second half of 2024. The company recorded income from operations of $0.7 million, slightly down from $0.8 million in the prior year period. Net loss for the quarter was $2.1 million, or $0.03 per share, compared to net income of $1.8 million, or $0.03 per share, in the same quarter last year. Cash and cash equivalents stood at $0.3 million as of September 30, 2025, compared to $1.4 million at the end of 2024.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Emmaus Life Sciences Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LA25075) on November 14, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2583568194"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2583568194\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2583568194?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-15 04:58","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2583568194","market":"nz","top_or_hot":-1,"title":"Emmaus Life Sciences Reports 38% Decline in Net Revenues for Q3 2025","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/EMMA\">Emmaus Life</a> Sciences Reports 38% Decline in Net Revenues for Q3 2025\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/EMMAW\">Emmaus Life</a> Sciences Inc. reported net revenues of $3.4 million for the three months ended September 30, 2025, a 38% decrease compared to $5.5 million in the same period in 2024. The decline was attributed to competition from generic L-Glutamine in the U.S. and lower sales in the Middle East North Africa region. Operating expenses were reduced to $2.4 million from $4.3 million, reflecting cost-cutting measures implemented in the second half of 2024. The company recorded income from operations of $0.7 million, slightly down from $0.8 million in the prior year period. Net loss for the quarter was $2.1 million, or $0.03 per share, compared to net income of $1.8 million, or $0.03 per share, in the same quarter last year. Cash and cash equivalents stood at $0.3 million as of September 30, 2025, compared to $1.4 million at the end of 2024.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Emmaus Life Sciences Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LA25075) on November 14, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Emmaus Life Sciences Reports 38% Decline in Net Revenues for Q3 2025</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEmmaus Life Sciences Reports 38% Decline in Net Revenues for Q3 2025\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-15 04:58</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/EMMA\">Emmaus Life</a> Sciences Reports 38% Decline in Net Revenues for Q3 2025\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/EMMAW\">Emmaus Life</a> Sciences Inc. reported net revenues of $3.4 million for the three months ended September 30, 2025, a 38% decrease compared to $5.5 million in the same period in 2024. The decline was attributed to competition from generic L-Glutamine in the U.S. and lower sales in the Middle East North Africa region. Operating expenses were reduced to $2.4 million from $4.3 million, reflecting cost-cutting measures implemented in the second half of 2024. The company recorded income from operations of $0.7 million, slightly down from $0.8 million in the prior year period. Net loss for the quarter was $2.1 million, or $0.03 per share, compared to net income of $1.8 million, or $0.03 per share, in the same quarter last year. Cash and cash equivalents stood at $0.3 million as of September 30, 2025, compared to $1.4 million at the end of 2024.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Emmaus Life Sciences Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LA25075) on November 14, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"EMMA","symbol_name":"Emmaus生命科学","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251114:nNDL9DzLXz:1","article_id":"2583568194","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2583568194","pubTimestamp":1763153891,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Emmaus Life Sciences Inc. reported net revenues of $3.4 million for the three months ended September 30, 2025, a 38% decrease compared to $5.5 million in the same period in 2024. The decline was attributed to competition from generic L-Glutamine in the U.S. and lower sales in the Middle East North Africa region. Operating expenses were reduced to $2.4 million from $4.3 million, reflecting cost-cutting measures implemented in the second half of 2024. The company recorded income from operations of $0.7 million, slightly down from $0.8 million in the prior year period. Net loss for the quarter was $2.1 million, or $0.03 per share, compared to net income of $1.8 million, or $0.03 per share, in the same quarter last year. Cash and cash equivalents stood at $0.3 million as of September 30, 2025, compared to $1.4 million at the end of 2024.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"EMMA":"Emmaus生命科学","BK4007":"制药"},"translate_title":"Emmaus Life Sciences报告2025年第三季度净收入下降38%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"EMMA":0.9},"content_text":"Emmaus Life Sciences Reports 38% Decline in Net Revenues for Q3 2025\n    \n\nEmmaus Life Sciences Inc. reported net revenues of $3.4 million for the three months ended September 30, 2025, a 38% decrease compared to $5.5 million in the same period in 2024. The decline was attributed to competition from generic L-Glutamine in the U.S. and lower sales in the Middle East North Africa region. Operating expenses were reduced to $2.4 million from $4.3 million, reflecting cost-cutting measures implemented in the second half of 2024. The company recorded income from operations of $0.7 million, slightly down from $0.8 million in the prior year period. Net loss for the quarter was $2.1 million, or $0.03 per share, compared to net income of $1.8 million, or $0.03 per share, in the same quarter last year. Cash and cash equivalents stood at $0.3 million as of September 30, 2025, compared to $1.4 million at the end of 2024.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Emmaus Life Sciences Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LA25075) on November 14, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-2","news_tag":"dataReport,express","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}